Verve Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-200.07	-157.39	-120.31	-45.7	-19.3
Depreciation & Amortization	12.25	6.71	3.38	1.33	0.11
Share-Based Compensation	35.12	22.48	7.07	0.85	0.45
Other Operating Activities	3.16	5.87	31.99	8.26	11.3
Operating Cash Flow	-149.55	-122.33	-77.88	-35.27	-7.44
Capital Expenditures	-9.28	-13.23	-4.36	-3.42	-1.86
Change in Investments	36.97	-142.72	-234.74	-47.7	-10.9
Investing Cash Flow	27.69	-155.96	-239.1	-51.13	-12.76
Share Issuance / Repurchase	213.04	329.74	286.96	0.01	0
Debt Issued / Paid	0	0	0	0	-0.09
Other Financing Activities	-0.46	-0.78	90.13	92.62	18.04
Financing Cash Flow	212.58	328.96	377.09	92.63	17.95
Net Cash Flow	90.72	50.67	60.11	6.24	-2.25
Free Cash Flow	-158.83	-135.56	-82.24	-38.69	-9.3
Free Cash Flow Margin	-1350.84%	-6984.23%	-	-	-
Free Cash Flow Per Share	-2.48	-2.51	-3.06	-17.19	-7.28

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).